Equities research analysts expect PAREXEL International Corporation (NASDAQ:PRXL) to report sales of $537.57 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for PAREXEL International Corporation’s earnings. The lowest sales estimate is $533.80 million and the highest is $540.30 million. PAREXEL International Corporation reported sales of $538.60 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 0.2%. The company is scheduled to announce its next quarterly earnings report on Wednesday, August 2nd.

According to Zacks, analysts expect that PAREXEL International Corporation will report full-year sales of $537.57 million for the current year, with estimates ranging from $2.09 billion to $2.10 billion. For the next year, analysts expect that the business will report sales of $2.20 billion per share, with estimates ranging from $2.17 billion to $2.22 billion. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for PAREXEL International Corporation.

Several equities research analysts recently issued reports on PRXL shares. BidaskClub lowered shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Mizuho increased their target price on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, May 30th. Barclays PLC reissued an “overweight” rating and issued a $87.00 target price on shares of PAREXEL International Corporation in a report on Wednesday, May 17th. Evercore ISI raised shares of PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 target price for the company in a report on Monday, May 15th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $88.10 target price on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $74.26.

PAREXEL International Corporation (PRXL) opened at 87.65 on Tuesday. The company’s 50-day moving average is $86.66 and its 200 day moving average is $73.05. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.86. The stock has a market cap of $4.45 billion, a PE ratio of 38.53 and a beta of 0.79.

A number of large investors have recently made changes to their positions in PRXL. World Asset Management Inc raised its position in PAREXEL International Corporation by 0.3% in the second quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock worth $279,000 after buying an additional 9 shares during the period. Public Employees Retirement System of Ohio raised its position in PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after buying an additional 73 shares during the period. Meadow Creek Investment Management LLC raised its position in PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after buying an additional 132 shares during the period. Baird Financial Group Inc. raised its position in PAREXEL International Corporation by 2.3% in the first quarter. Baird Financial Group Inc. now owns 5,812 shares of the medical research company’s stock worth $367,000 after buying an additional 133 shares during the period. Finally, Isthmus Partners LLC raised its position in PAREXEL International Corporation by 1.3% in the first quarter. Isthmus Partners LLC now owns 11,516 shares of the medical research company’s stock worth $727,000 after buying an additional 145 shares during the period. 93.48% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/parexel-international-corporation-prxl-expected-to-announce-quarterly-sales-of-537-57-million-2.html.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Get a free copy of the Zacks research report on PAREXEL International Corporation (PRXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.